Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

An evaluation of positive behavioural support implemented within an intensive community support service for people with learning disabilities who present with behaviours that challenge.

Lewis N, Reynolds E, Vale M, Keenan E, Hartland A, Haines M, Davies BE.

J Intellect Disabil. 2019 Dec 13:1744629519890962. doi: 10.1177/1744629519890962. [Epub ahead of print]

PMID:
31835956
2.

The society for environmental Geochemistry and health (SEGH): a retrospect.

Wixson BG, Davies BE.

Environ Geochem Health. 2020 Feb;42(2):349-351. doi: 10.1007/s10653-019-00262-1. No abstract available.

PMID:
30796635
3.

Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.

Nnane IP, Plotnikov AH, Peters G, Johnson M, Kojak C, Vutikullird A, Ariyawansa J, De Vries R, Davies BE.

Clin Pharmacokinet. 2016 Feb;55(2):225-36. doi: 10.1007/s40262-015-0309-8.

PMID:
26242382
4.

A PBPK model describing a xenobiotic with a short PK event scale.

Wang X, Davies BE.

J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):409-16. doi: 10.1007/s10928-015-9425-1. Epub 2015 Jul 9.

PMID:
26156591
5.

A study examining the relationship between alexithymia and challenging behaviour in adults with intellectual disability.

Davies BE, Frude N, Jenkins R, Hill C, Harding C.

J Intellect Disabil Res. 2015 Nov;59(11):1022-32. doi: 10.1111/jir.12186. Epub 2015 Feb 13.

PMID:
25683670
6.

The UK geochemical environment and cardiovascular diseases: magnesium in food and water.

Davies BE.

Environ Geochem Health. 2015 Jun;37(3):411-27. doi: 10.1007/s10653-014-9671-y. Epub 2014 Dec 21. Review.

PMID:
25528218
7.

Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study.

Cirrincione-Dall G, Brennan BJ, Ballester-Sanchis RM, Navarro MT, Davies BE.

J Clin Pharmacol. 2012 Aug;52(8):1255-64. doi: 10.1177/0091270011412960. Epub 2011 Oct 30.

PMID:
22039289
8.

Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.

Uchimura N, Kuwahara H, Kumagai Y, Mishima K, Inoue Y, Rayner CR, Toovey S, Davies BE, Hosaka Y, Abe M, Prinssen EP.

Basic Clin Pharmacol Toxicol. 2011 Oct;109(4):309-14. doi: 10.1111/j.1742-7843.2011.00726.x. Epub 2011 Jun 29.

9.
10.

Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients.

Davies BE, Aceves Baldó P, Lennon-Chrimes S, Brewster M.

Br J Clin Pharmacol. 2010 Dec;70(6):834-43. doi: 10.1111/j.1365-2125.2010.03780.x.

11.

Exploring cell tropism as a possible contributor to influenza infection severity.

Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA.

PLoS One. 2010 Nov 23;5(11):e13811. doi: 10.1371/journal.pone.0013811.

12.

Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.

Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA.

J Theor Biol. 2011 Jan 21;269(1):234-44. doi: 10.1016/j.jtbi.2010.10.017. Epub 2010 Oct 21.

PMID:
20970433
13.

Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.

Davies BE.

J Antimicrob Chemother. 2010 Apr;65 Suppl 2:ii5-ii10. doi: 10.1093/jac/dkq015. Review.

14.

Safety and pharmacokinetics of oseltamivir at standard and high dosages.

Dutkowski R, Smith JR, Davies BE.

Int J Antimicrob Agents. 2010 May;35(5):461-7. doi: 10.1016/j.ijantimicag.2009.12.023. Epub 2010 Mar 1.

PMID:
20189775
15.

Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.

Mallalieu NL, Lennon S, Guy T, Liu M, Luedin E, Davies BE.

Br J Clin Pharmacol. 2009 Apr;67(4):469-72. doi: 10.1111/j.1365-2125.2009.03367.x.

16.

Pruritic acral rash in a child. Gianotti-Crosti syndrome.

Xia Y, Davies BE, Gunning S.

Am Fam Physician. 2008 Jul 1;78(1):103-5. No abstract available.

17.

Protective values for soil lead with respect to child health: a critique of UK guidelines.

Davies BE.

Environ Geochem Health. 2008 Dec;30(6):639-46. doi: 10.1007/s10653-008-9192-7.

PMID:
18546055
18.

Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.

Mallalieu NL, Lennon S, Liu M, Kirkpatrick C, Robson R, Luedin E, Davies BE.

Antimicrob Agents Chemother. 2008 Jul;52(7):2360-6. doi: 10.1128/AAC.01249-07. Epub 2008 Apr 28.

19.

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.

Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE.

J Clin Pharmacol. 2007 Sep;47(9):1119-28.

PMID:
17766699
20.

Variation of metals in bed sediments of Qaraaoun Reservoir, Lebanon.

Korfali SI, Jurdi M, Davies BE.

Environ Monit Assess. 2006 Apr;115(1-3):307-19. Epub 2006 Apr 30.

PMID:
16649137
21.

Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men.

Brennan BJ, Brown AB, Kolis SJ, Rutman O, Gooden C, Davies BE.

J Clin Pharmacol. 2006 Feb;46(2):222-8.

PMID:
16432274
22.
23.

A comparison of metals in sediments and water in the River Nahr-Ibrahim, Lebanon: 1996 and 1999.

Korfali SI, Davies BE.

Environ Geochem Health. 2003 Mar;25(1):41-50.

PMID:
12901077
24.

Evaluation of water quality of the Qaraaoun Reservoir, Lebanon: suitability for multipurpose usage.

Jurdi M, Korfali SI, Karahagopian Y, Davies BE.

Environ Monit Assess. 2002 Jul;77(1):11-30.

PMID:
12139073
25.

A preliminary electron backscattered diffraction study of sintered NdFeB-type magnets.

Lillywhite SJ, Williams AJ, Davies BE, Harris IR.

J Microsc. 2002 Mar;205(Pt 3):270-7.

26.

Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.

Davies BE, Kirchin MA, Bensel K, Lorusso V, Davies A, Parker JR, Lafrance ND.

Invest Radiol. 2002 May;37(5):299-308.

PMID:
11979156
27.

Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.

Townsend RR, Cohen DL, Katholi R, Swan SK, Davies BE, Bensel K, Lambrecht L, Parker J.

Am J Kidney Dis. 2000 Dec;36(6):1207-12.

PMID:
11096046
28.

Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.

Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND.

Invest Radiol. 1999 Jul;34(7):443-8.

PMID:
10399633
29.

The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.

Davies BE, Minthorn EA, Dennis MJ, Rosing H, Beijnen JH.

Pharm Res. 1997 Oct;14(10):1461-5.

PMID:
9358562
30.

Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients.

Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, Boppana V, Levitt B, Davies BE, Nemunaitis J, Jorkasky DK.

Pharm Res. 1996 May;13(5):794-7.

PMID:
8860439
31.

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.

van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH.

Cancer Chemother Pharmacol. 1996;38(3):254-60.

PMID:
8646800
32.

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH.

J Clin Oncol. 1995 Jul;13(7):1768-76.

PMID:
7602366
33.
34.

Distribution of metals in mechanical fractions of soils from a lake catchment in Venezuela.

Mogollón' JL, Bifano C, Davies BE.

Environ Geochem Health. 1995 Jun;17(2):103-11. doi: 10.1007/BF00146712.

PMID:
24194122
35.

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.

van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, Maes RA, Beijnen JH.

Cancer Chemother Pharmacol. 1995;35(3):237-45.

PMID:
7805183
36.

Trace elements in the human environment: Problems and risks.

Davies BE.

Environ Geochem Health. 1994 Dec;16(3-4):97-106. doi: 10.1007/BF01747905.

PMID:
24197203
37.

Change in ownership of environmental geochemistry and health.

Davies BE.

Environ Geochem Health. 1994 Dec;16(3-4):96. doi: 10.1007/BF01747903. No abstract available.

PMID:
24197201
38.

Editorial.

Davies BE.

Environ Geochem Health. 1993 Sep;15(2-3):58. doi: 10.1007/BF02627821. No abstract available.

PMID:
24198099
39.

Leaded windows as a source of lead within homes.

al-Radady AS, Davies BE, French MJ.

Sci Total Environ. 1993 Apr 15;132(1):43-51.

PMID:
8475367
40.

A mutual admiration society?

Davies BE.

Environ Geochem Health. 1993 Mar;15(1):2. doi: 10.1007/BF00146286. No abstract available.

PMID:
24198075
41.

Editorial: A new look.

Davies BE.

Environ Geochem Health. 1992 Dec;14(4):102. doi: 10.1007/BF01783483. No abstract available.

PMID:
24198041
42.

Editorial.

Davies BE.

Environ Geochem Health. 1992 Jun;14(2):34. doi: 10.1007/BF01783624. No abstract available.

PMID:
24197922
43.

Radioactivity in the environment.

Davies BE, Pavely CF.

Environ Geochem Health. 1991 Sep;13(3):138. doi: 10.1007/BF01758543. No abstract available.

PMID:
24202942
44.

Heavy metals in soils in north Somerset, England, with special reference to contamination from base metal mining in the Mendips.

Davies BE, Bailinger RC.

Environ Geochem Health. 1990 Dec;12(4):291-300. doi: 10.1007/BF01783454.

PMID:
24202661
45.

Temocillin: lymph penetration and protein binding.

Staniforth DH, Clarke H, Davies BE.

Int J Clin Pharmacol Ther Toxicol. 1990 Jul;28(7):286-91.

PMID:
2201651
46.

Editorial.

Davies BE.

Environ Geochem Health. 1990 Mar;12(1-2):2. doi: 10.1007/BF01734041. No abstract available.

PMID:
24202558
47.

Data handling and pattern recognition for metal contaminated soils.

Davies BE.

Environ Geochem Health. 1989 Dec;11(3-4):137-43. doi: 10.1007/BF01758663.

PMID:
24202423
48.

Editorial.

Davies BE.

Environ Geochem Health. 1989 Dec;11(3-4):74. doi: 10.1007/BF01758652. No abstract available.

PMID:
24202412
49.

Pharmacokinetics of cromakalim--a new antihypertensive agent, in patients with mild essential hypertension.

Carey OJ, Fleming JJ, Ward JW, Davies BE.

Xenobiotica. 1989 Jan;19(1):93-5. No abstract available.

PMID:
2756721
50.

Editorial.

Davies BE.

Environ Geochem Health. 1988 Dec;10(3-4):70. doi: 10.1007/BF01758670. No abstract available.

PMID:
24213642

Supplemental Content

Loading ...
Support Center